Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)

Trial Profile

Prospective Randomized Double-Blind, Placebo Controlled Evaluation of the Pharmacokinetics, Safety and Efficacy of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia (PRESERVE-1)

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Antithrombin alfa (Primary)
  • Indications Preeclampsia
  • Focus Registrational; Therapeutic Use
  • Acronyms PRESERVE-1
  • Sponsors rEVO Biologics
  • Most Recent Events

    • 07 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 08 Apr 2016 Planned End Date changed from 1 Oct 2016 to 1 Nov 2016 as reported by ClinicalTrials.gov.
    • 08 Apr 2016 Planned primary completion date changed from 1 Jun 2016 to 1 May 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top